Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial

Lupus nephritis (LN) is typically treated with intravenous cyclophosphamide (IVCY), which is associated with serious adverse effects. Tacrolimus may be an alternative for initial treatment of LN; however, large-scale, randomized clinical studies of tacrolimus are lacking. To assess efficacy and safe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA network open 2022-03, Vol.5 (3), p.e224492-e224492
Hauptverfasser:	Zheng, Zhaohui, Zhang, Haitao, Peng, Xiaomei, Zhang, Chun, Xing, Changying, Xu, Gang, Fu, Ping, Ni, Zhaohui, Chen, Jianghua, Xu, Zhonggao, Zhao, Ming-Hui, Li, Shaomei, Huang, Xiangyang, Miao, Lining, Chen, Xiaonong, Liu, Bicheng, He, Yongcheng, Li, Jing, Liu, Lijun, Kadeerbai, Haishan, Liu, Zhangsuo, Liu, Zhihong
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Clinical trials Cyclophosphamide - adverse effects Cyclophosphamide - therapeutic use Drug Therapy, Combination Female Humans Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Lupus Lupus Nephritis - drug therapy Male Online Only Original Investigation Response rates Rheumatology Tacrolimus - adverse effects Tacrolimus - therapeutic use Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!